About Altimmune (ALT)

Altimmune Inc (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing and commercializing novel immunotherapeutic products for infectious diseases and cancer. The company's lead product candidate is NasoVAX, a single-dose intranasal vaccine for the prevention of influenza, currently in phase 2 clinical trials. Altimmune is also developing other candidates in its pipeline, including HepTcell, a therapeutic vaccine for chronic hepatitis B, and SparVax-L, a next-generation anthrax vaccine. The company utilizes its proprietary platform technologies, including its Densigen and MimiVax platforms, to develop and produce its immunotherapeutic products.

Altimmune's stock price has experienced significant volatility in recent years. In 2017, the stock reached a peak of $35 per share, but has since declined to its current price of around $4 per share. This decline is largely attributed to the failure of the company's phase 2 clinical trial for HepTcell, which led to a significant decrease in investor confidence. However, Altimmune has since refocused its efforts on its NasoVAX program, which has shown promising results in early clinical trials. The company is confident in the potential of NasoVAX to address the significant unmet need for a universal influenza vaccine and is actively advancing the candidate through clinical development.